The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab.
(2011) Alimentary Pharmacology and Therapeutics. Symposium Series — Vol. 33, n° 3, p. 349-357 (2011)
Files
pdfdocument.pdf
Restricted Access - Adobe PDF
- 197.68 KB
Details
- Authors
- Abstract
- Patients treated with infliximab for Crohn's disease (CD) frequently require intensified dosage due to loss of response. There are scant data regarding the efficacy of shortening the dosing interval to 6 weeks.
- Affiliations
Citations
Kopylov, U., Mantzaris, G. J., Katsanos, K. H., Reenaers, C., Ellul, P., Rahier, J.-F., Israeli, E., Lakatos, P. L., Fiorino, G., Cesarini, M., Tsianos, E. V., Louis, E., & Ben-Horin, S. (2011). The efficacy of shortening the dosing interval to once every six weeks in Crohn’s patients losing response to maintenance dose of infliximab. Alimentary Pharmacology and Therapeutics. Symposium Series, 33(3), 349-357. https://doi.org/10.1111/j.1365-2036.2010.04523.x (Original work published 2011)